Author

David Zahrieh

Observed names: D. M. Zahrieh, D. Zahrieh, D.M. Zahrieh, Zahrieh, D.M.

Institution: Mayo Clinic

Observed institution: Mayo Clinic

ORCID: 0000-0002-5106-1730

Observed ORCIDs: 0000-0002-5106-1730, 0000-0003-0529-5146

OpenAlex ID: A5122069130

Alliance A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II Study

2026 · Ellen M. Lavoie Smith, Minji Lee, et al. · JCO oncology advances. · 3

Accuracy of Index Lymph Node Pathology in Predicting Overall Response to Neoadjuvant Immunotherapy for Clinical Stage III Melanoma: Results From the Prospective NeoACTIVATE Arm C (NCT03554083) Substudy

2026 · Tina J. Hieken, Thomas J. Flotte, et al. · Annals of Surgical Oncology · 1

Data from Was It Worth It? Response Data from >650 US and International Participants in Chemoprevention Trials

2026 · David Zahrieh, Carrie A. Strand, et al. · 1

Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)

2026 · Bjelic-Radisic, V., Lemieux, J., et al. · UNC Libraries

ASO Visual Abstract: Accuracy of Index Lymph Node Pathology in Predicting Overall Response to Neoadjuvant Immunotherapy for Clinical Stage III Melanoma—Results from the Prospective NeoACTIVATE Arm C (NCT03554083) Substudy

2026 · Tina J. Hieken, Thomas J. Flotte, et al. · Annals of Surgical Oncology

Prognostic value of an MRI-derived recurrence assay in women with hormone receptor–positive, HER2-negative breast cancer: A retrospective, multi-center analysis.

2026 · Matthew P. Goetz, Qinmei Xu, et al. · Journal of Clinical Oncology

Placebo Response in Phase II-III Symptom Intervention Studies: A Focus on Chemotherapy-Induced Peripheral Neuropathy and Associated Neuropathic Pain

2026 · David Zahrieh, Daniel Satele, et al. · Cancers

Abstract 1200: Spatially resolved tumor-cell MHC class II shapes adaptive immunity and therapeutic response in triple-negative breast cancer.

2026 · Yi Liu, Sachin Kumar Deshmukh, et al. · Cancer Research

Abstract PS1-10-22: Tumor-infiltrating lymphocytes in advanced ER-positive, HER2-negative breast cancer prior to treatment with palbociclib and endocrine therapy: a retrospective analysis of the PROMISE study

2026 · C. C. O'Sullivan, A. M. Moyer, et al. · Clinical Cancer Research

Abstract PS5-07-20: Trial in progress: Phase 1 Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer (NCI Protocol #10546)

2026 · R. Leon-Ferre, D. M. Zahrieh, et al. · Clinical Cancer Research

Supplementary Table S1 from Was It Worth It? Response Data from >650 US and International Participants in Chemoprevention Trials

2026 · David Zahrieh, Carrie A. Strand, et al.

Supplementary Table S2 from Was It Worth It? Response Data from >650 US and International Participants in Chemoprevention Trials

2026 · David Zahrieh, Carrie A. Strand, et al.

Supplementary Figure S2 from Was It Worth It? Response Data from >650 US and International Participants in Chemoprevention Trials

2026 · David Zahrieh, Carrie A. Strand, et al.

Supplementary Figure S1 from Was It Worth It? Response Data from >650 US and International Participants in Chemoprevention Trials

2026 · David Zahrieh, Carrie A. Strand, et al.

Supplementary Table S4 from Was It Worth It? Response Data from >650 US and International Participants in Chemoprevention Trials

2026 · David Zahrieh, Carrie A. Strand, et al.

Supplementary Table S3 from Was It Worth It? Response Data from >650 US and International Participants in Chemoprevention Trials

2026 · David Zahrieh, Carrie A. Strand, et al.

Prospective Multicenter Study to Test the Fidelity of Index Lymph Node Pathology Assessment in Predicting Pathologic Status of the Nodal Basin for Neoadjuvant-treated Stage III Melanoma

2025 · T. Hieken, T. Flotte, et al. · European Journal of Surgical Oncology

Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)

2025 · M.J. Naughton, D.M. Zahrieh, et al. · ESMO Open

Works count: 18

Citation count: 5

H-index: 1

I10-index: